These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17470784)

  • 1. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
    Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
    Newbold A; Lindemann RK; Cluse LA; Whitecross KF; Dear AE; Johnstone RW
    Mol Cancer Ther; 2008 May; 7(5):1066-79. PubMed ID: 18483296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
    Ellis L; Bots M; Lindemann RK; Bolden JE; Newbold A; Cluse LA; Scott CL; Strasser A; Atadja P; Lowe SW; Johnstone RW
    Blood; 2009 Jul; 114(2):380-93. PubMed ID: 19383971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.
    Whitecross KF; Alsop AE; Cluse LA; Wiegmans A; Banks KM; Coomans C; Peart MJ; Newbold A; Lindemann RK; Johnstone RW
    Blood; 2009 Feb; 113(9):1982-91. PubMed ID: 19060243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.
    Inoue S; Riley J; Gant TW; Dyer MJ; Cohen GM
    Leukemia; 2007 Aug; 21(8):1773-82. PubMed ID: 17525724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
    Renault TT; Elkholi R; Bharti A; Chipuk JE
    J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
    Thompson RC; Vardinogiannis I; Gilmore TD
    PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
    Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
    Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
    Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
    Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
    Gillespie S; Borrow J; Zhang XD; Hersey P
    Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
    Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
    Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.
    Happo L; Cragg MS; Phipson B; Haga JM; Jansen ES; Herold MJ; Dewson G; Michalak EM; Vandenberg CJ; Smyth GK; Strasser A; Cory S; Scott CL
    Blood; 2010 Dec; 116(24):5256-67. PubMed ID: 20829369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
    Wiegmans AP; Alsop AE; Bots M; Cluse LA; Williams SP; Banks KM; Ralli R; Scott CL; Frenzel A; Villunger A; Johnstone RW
    Cancer Res; 2011 May; 71(10):3603-15. PubMed ID: 21398407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
    Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
    Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.
    Jiang X; Tsang YH; Yu Q
    Int J Biochem Cell Biol; 2007; 39(5):1016-25. PubMed ID: 17331788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).
    Henderson C; Mizzau M; Paroni G; Maestro R; Schneider C; Brancolini C
    J Biol Chem; 2003 Apr; 278(14):12579-89. PubMed ID: 12556448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.
    Zhao Y; Tan J; Zhuang L; Jiang X; Liu ET; Yu Q
    Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16090-5. PubMed ID: 16243973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
    Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.